Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02881567
Recruitment Status : Terminated (Study terminated in line with Biogen decision to withdraw Zinbryta from the market and not to pursue further studies of daclizumab in MS.)
First Posted : August 29, 2016
Results First Posted : September 24, 2019
Last Update Posted : September 27, 2019
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Biogen

Brief Summary:
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The secondary objectives of this study in this study population are to evaluate the effects of daclizumab on the following: 1) Multiple Sclerosis (MS) relapse activity including the annualized relapse rate (ARR) and the proportion of participants experiencing relapses requiring hospitalization and/or steroid treatment; 2) MS-related outcomes measured using magnetic resonance imaging (MRI); 3) Safety and tolerability in participants previously treated with natalizumab.

Condition or disease Intervention/treatment Phase
Relapsing-Remitting Multiple Sclerosis (RRMS) Drug: Daclizumab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)
Actual Study Start Date : April 18, 2017
Actual Primary Completion Date : September 12, 2018
Actual Study Completion Date : September 12, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Daclizumab Drug: Daclizumab
High yield formulation
Other Names:
  • BIIB019
  • Zinbryta




Primary Outcome Measures :
  1. Percentage of Participants Relapse-free at Month 6 [ Time Frame: Month 6 ]
    Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist. The Kaplan-Meier estimate of the percentage of participants relapse-free at Month 6 is reported.


Secondary Outcome Measures :
  1. Percentage of Participants Relapse-free at Month 12 [ Time Frame: Month 12 ]
    Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.

  2. Percentage of Participants Experiencing Relapse Requiring Hospitalization and/or Steroid Treatment at Month 12 [ Time Frame: Month 12 ]
    Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.

  3. Annualized Relapse Rate (ARR) at Month 12 [ Time Frame: Month 12 ]
    Relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist. The ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of Month 12, and the ratio then multiplied by 365.

  4. Number of Participants With New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions at Months 6 and 12 [ Time Frame: Months 6 and 12 ]
    New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions were assessed using magnetic resonance imaging (MRI).

  5. Number of Participants With New and Newly Enlarged T2 Hypointense Lesions at Months 6 and 12 [ Time Frame: Months 6 and 12 ]
    New and newly enlarged T2 Hypointense Lesions were measured by MRI.

  6. Permanent Discontinuation Rate of Daclizumab at Month 12 [ Time Frame: Month 12 ]
    Permanent Discontinuation Rate was calculated as the ratio of number of participants who had permanently discontinued daclizumab prior to Month 12 over the total number of participants who received at least 1 dose of daclizumab in the study.

  7. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: First dose of study drug to within 30 days of last dose (up to 11 months) ]
    An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death or in the view of the Investigator, places the participant at immediate risk of death or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability or results in a birth defect.

  8. Number of Participants With Clinically Relevant Shifts in Laboratory Assessments [ Time Frame: First dose of study drug to within 30 days of last dose (up to 11 months) ]
    Clinical Laboratory assessments were tests of Chemistry and Hematology. The investigator determined if any of the laboratory results were clinically relevant shifts from Baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  • Must have documented diagnosis of RRMS (McDonald 2010 Criteria) at screening [Polman 2011].
  • Must have been treated with natalizumab for at least the 12 months prior to screening and have not missed 2 or more consecutive scheduled doses.
  • Must be naïve to daclizumab and other forms of daclizumab such as Zenapax® prior to enrollment.
  • Must have a confirmed Expanded Disability Status Scale (EDSS) score of 0 to 5.5, inclusive, at screening.
  • Female participants of childbearing potential must practice effective contraception from Day -1 and be willing and able to continue contraception for duration of the study.

Key Exclusion Criteria

  • Current participation in another investigational study.
  • Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold) [Lublin 2014].
  • Females breastfeeding, pregnant, or planning to become pregnant; or women who have a positive pregnancy test result during screening.
  • History of drug or alcohol abuse (as defined by the Investigator) within 1 year prior to screening.
  • History of severe hypersensitivity (e.g., anaphylaxis or anaphylactoid reactions) to the active ingredient or any of the excipients.
  • History of severe opportunistic infections (including progressive multifocal leukoencephalopathy (PML)) or any clinically significant, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (other than MS), dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator.
  • Discontinued natalizumab due to suspicion of PML.
  • Known active malignancies (participants with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).
  • The participant is using another MS therapy concomitantly.
  • Known history of human immunodeficiency virus (HIV).
  • Positive test result for Hepatitis C virus (test for hepatitis C virus antibody [HCV Ab]) or hepatitis B virus (test for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]).
  • The participant has been treated with immunosuppressive or immunomodulating treatments including mitoxantrone, azathioprine, methotrexate, cyclophosphamide, or mycophenolate mofetil.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02881567


Locations
Layout table for location information
United States, Florida
Research Site
Tampa, Florida, United States, 33612
United States, Iowa
Research Site
Des Moines, Iowa, United States, 50314
United States, Wisconsin
Research Site
Milwaukee, Wisconsin, United States, 53501
Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 2G3
Germany
Research Site
Muenchen, Bayern, Germany, 81675
Research Site
Potsdam, Brandenburg, Germany, 14471
Research Site
Dresden, Sachsen, Germany, 01307
Research Site
Hamburg, Germany, 20249
Italy
Research Site
Pozzilli, Isernia, Italy, 86077
Research Site
Napoli, Italy, 80131
Puerto Rico
Research Site
Guaynabo, Puerto Rico, 00968
Sponsors and Collaborators
Biogen
AbbVie
Investigators
Layout table for investigator information
Study Director: Medical Director Biogen
  Study Documents (Full-Text)

Documents provided by Biogen:
Statistical Analysis Plan  [PDF] June 14, 2018
Study Protocol  [PDF] July 6, 2016


Layout table for additonal information
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT02881567    
Other Study ID Numbers: 205MS305
2016-002820-10 ( EudraCT Number )
First Posted: August 29, 2016    Key Record Dates
Results First Posted: September 24, 2019
Last Update Posted: September 27, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Biogen:
Multiple Sclerosis
Daclizumab
Tysabri-Switch
Additional relevant MeSH terms:
Layout table for MeSH terms
Daclizumab
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Natalizumab
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents